DK1278758T3 - Combretastatin A-1-phosphat- og combretastatin B-1-phosphat-prodrugs - Google Patents

Combretastatin A-1-phosphat- og combretastatin B-1-phosphat-prodrugs

Info

Publication number
DK1278758T3
DK1278758T3 DK01928978.4T DK01928978T DK1278758T3 DK 1278758 T3 DK1278758 T3 DK 1278758T3 DK 01928978 T DK01928978 T DK 01928978T DK 1278758 T3 DK1278758 T3 DK 1278758T3
Authority
DK
Denmark
Prior art keywords
phosphate
combretastatin
prodrugs
combretastin
prodrug
Prior art date
Application number
DK01928978.4T
Other languages
English (en)
Inventor
George R Pettit
John W Lippert Iii
Original Assignee
Univ Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Arizona filed Critical Univ Arizona
Application granted granted Critical
Publication of DK1278758T3 publication Critical patent/DK1278758T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C07C255/43—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C07D453/04—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
DK01928978.4T 2000-04-27 2001-04-27 Combretastatin A-1-phosphat- og combretastatin B-1-phosphat-prodrugs DK1278758T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20039500P 2000-04-27 2000-04-27
PCT/US2001/013858 WO2001081355A1 (en) 2000-04-27 2001-04-27 Combretastatin a-1 phosphate and combretastatin b-1 phosphate prodrugs

Publications (1)

Publication Number Publication Date
DK1278758T3 true DK1278758T3 (da) 2012-01-23

Family

ID=22741540

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01928978.4T DK1278758T3 (da) 2000-04-27 2001-04-27 Combretastatin A-1-phosphat- og combretastatin B-1-phosphat-prodrugs

Country Status (9)

Country Link
US (1) US7078552B2 (da)
EP (1) EP1278758B1 (da)
AT (1) ATE527271T1 (da)
CA (1) CA2407675C (da)
CY (1) CY1112310T1 (da)
DK (1) DK1278758T3 (da)
ES (1) ES2395097T3 (da)
PT (1) PT1278758E (da)
WO (1) WO2001081355A1 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078552B2 (en) * 2000-04-27 2006-07-18 Arizona Board Of Regents Combretastatin A-1 phosphate and combretastatin B-1 phosphate prodrugs
CA2463902A1 (en) 2001-10-26 2003-05-01 Oxigene, Inc. Functionalized stilbene derivatives as improved vascular targeting agents
US20090137687A1 (en) * 2003-02-28 2009-05-28 Oxigene, Inc. Compositions and Methods With Enhanced Therapeutic Activity
AU2004218412A1 (en) 2003-02-28 2004-09-16 Oxigene, Inc. Compositions and methods with enhanced therapeutic activity
GB0504994D0 (en) 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
CN1907989B (zh) * 2005-08-02 2011-08-17 浙江天皇药业有限公司 毛兰素盐及其制备方法和包含其的药物组合物
US8440692B2 (en) * 2006-12-07 2013-05-14 China Medical University Hydrophilic derivatives of 2-aryl-4-quinolones as anticancer agents
WO2008103415A2 (en) * 2007-02-22 2008-08-28 Oxigene, Inc. Methods of preparing phosphoric acids of combretastatin and derivatives thereof
CA2703283C (en) 2007-11-21 2016-01-12 Oxigene, Inc. Method for treating hematopoietic neoplasms
WO2010132498A1 (en) * 2009-05-11 2010-11-18 Oxigene, Inc. Vascular disrupting agents for treatment of polypoidal choroidal vasculopathy
WO2011112988A1 (en) * 2010-03-11 2011-09-15 Oxigene, Inc. Ophthalmic formulations
WO2011151423A1 (en) 2010-06-04 2011-12-08 Exonhit S.A. Substituted isoquinolines and their use as tubulin polymerization inhibitors
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
US10201623B2 (en) 2013-03-15 2019-02-12 Memorial Sloan Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
WO2016130969A1 (en) 2015-02-13 2016-08-18 George Robert Pettit Silstatin compounds
EP3337495A4 (en) 2015-08-18 2019-04-10 Mateon Therapeutics, Inc. USE OF VDA TO ENHANCE IMMUNOMODULATION THERAPIES AGAINST TUMORS
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US11629167B2 (en) 2017-11-09 2023-04-18 Arizona Board Of Regents On Behalf Of Arizona State University Betulastatin compounds
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1338645C (en) * 1987-01-06 1996-10-15 George R. Pettit Isolation, structural elucidation and synthesis of novel antineoplastic substances denominated "combretastatins"
GB9106177D0 (en) * 1991-03-22 1991-05-08 Aston Molecules Ltd Substituted diphenylethylenes and analogues or derivatives thereof
US5561122A (en) * 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
WO1999035150A1 (en) 1998-01-09 1999-07-15 Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University Synthesis of combretastatin a-4 prodrugs and trans-isomers thereo f
JP2002500184A (ja) * 1998-01-09 2002-01-08 アリゾナ ボード オブ リーゼンツ フェンスタチンとそのプロドラッグの合成
GB9903403D0 (en) * 1999-02-16 1999-04-07 Angiogene Pharm Ltd Substituted stilbene compounds with vascular damaging activity
AU776511B2 (en) 1999-02-18 2004-09-09 Baylor University Compositions and methods for use in targeting vascular destruction
US7078552B2 (en) * 2000-04-27 2006-07-18 Arizona Board Of Regents Combretastatin A-1 phosphate and combretastatin B-1 phosphate prodrugs

Also Published As

Publication number Publication date
US20030220298A1 (en) 2003-11-27
EP1278758A1 (en) 2003-01-29
CY1112310T1 (el) 2015-12-09
EP1278758A4 (en) 2005-10-19
PT1278758E (pt) 2011-12-22
ATE527271T1 (de) 2011-10-15
CA2407675A1 (en) 2001-11-01
WO2001081355A1 (en) 2001-11-01
ES2395097T3 (es) 2013-02-08
EP1278758B1 (en) 2011-10-05
CA2407675C (en) 2012-07-10
US7078552B2 (en) 2006-07-18

Similar Documents

Publication Publication Date Title
CY1112310T1 (el) Προφαρμακα κομπρεταστατινης α1-φωσφορικης και κομπρεταστατινης β1-φωσφορικης
PT1309589E (pt) Compostos de ureia e metodos de utilizacao
HN2001000012A (es) Tratamiento de la enfermedad neurodegenerativa
IS2782B (is) Lyfja- og snyrtivörusamsetningar sem ná yfir þorskserínprótínasa og lyfja- og snyrtivörunotkun þeirra
NO20030748D0 (no) Prodruger av betulinsyre for behandlingen av kreft og HIV
BR9809819A (pt) Compostos e métodos para a inibição da expressão de vcam-1
DK0693281T3 (da) Farmaceutiske fluoxetinformuleringer
HN1999000096A (es) Formulaciones intranasales para tratar trastornos sexuales
CY1107927T1 (el) Ενωσεις φωσφονικου
DK1315506T3 (da) Phospholipidderivater af valproinsyre og blandinger deraf
ES2172695T3 (es) Carboxamidas y sulfonamidas de benzofurano.
TR200200260T2 (tr) N-desmetilzopiklonlarının üretim ve kullanım yöntemleri
HUP0103112A2 (hu) Glikogén foszforiláz inhibitorok alkalmazása daganatnövekedés gátlására
IS6621A (is) Þíenódíbensóasúlen efnasambönd sem hindrar fyrir æxlisdrepþátt
DE602004017871D1 (de) Zubereitungen zur behandlung von arthritischen erscheinungen
BRPI0415203A (pt) pentanóis reestruturados, um processo para sua produção e seu uso como agentes antiinflamatórios
AR021643A1 (es) Combinacion de cerivastatina y fibratos.
DK1001761T3 (da) Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsunderskudslidelser
PT994704E (pt) Utilizacao de analogos do gaba tal como a gabapentina no fabrico de um medicamento para o tratamento de doencas inflamatorias
NZ333232A (en) Use of p-aminophenol derivatives (paracetamol) to treat neurodegenerative disease
ES2170143T3 (es) Composiciones que comprenden halofantrina en una forma especial.
DE60026491D1 (de) Melagatran zur behandlung von entzündungen
BR9709264A (pt) Processo para produzir e composto
NO20003529L (no) Behandling av dyskinesi-tilstander
HUP9902417A2 (hu) Alfa-ketoészterek, és alfa-ketoamidok acilezett enol-származékai